TAM
NBIX icon

Tiverton Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Tiverton Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$5.02M Buy
55,692
+23,118
+71% +$2.16M 0.17% 118
2019
Q2 		$2.75M Buy
32,574
+1,739
+6% +$143K 0.1% 172
2019
Q1 		$2.72M Buy
30,835
+7,481
+32% +$625K 0.12% 147
2018
Q4 		$1.67M Buy
+23,354
New +$2.24M 0.1% 135

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tiverton Asset Management's NBIX Position: Q3 2019 in Review

Tiverton Asset Management increased its Neurocrine Biosciences (NBIX) stake by 71% in Q3 2019, buying an estimated $2.16M and bringing the position to 55,692 shares worth $5.02M. The position accounts for 0.17% of the portfolio, ranked #118.

Tiverton Asset Management first reported a position in NBIX in Q4 2018 and has held it in 4 quarters since. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Tiverton Asset Management held 55,692 shares of Neurocrine Biosciences worth $5.02M as of Q3 2019.
  • Tiverton Asset Management bought 23,118 Neurocrine Biosciences shares in Q3 2019, an estimated $2.16M.
  • Neurocrine Biosciences made up 0.17% of Tiverton Asset Management's portfolio in Q3 2019, its #118 holding.
  • Tiverton Asset Management first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 4 quarters since.
  • 332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.